Private Advisor Group LLC Lowers Position in Hologic Inc. (HOLX)
Private Advisor Group LLC reduced its stake in shares of Hologic Inc. (NASDAQ:HOLX) by 7.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,974 shares of the company’s stock after selling 788 shares during the period. Private Advisor Group LLC’s holdings in Hologic were worth $346,000 as of its most recent filing with the SEC.
Other institutional investors also recently modified their holdings of the company. Thompson Siegel & Walmsley LLC increased its position in shares of Hologic by 1.2% in the second quarter. Thompson Siegel & Walmsley LLC now owns 4,176 shares of the company’s stock valued at $144,000 after buying an additional 51 shares during the last quarter. Synovus Financial Corp increased its position in shares of Hologic by 35.6% in the second quarter. Synovus Financial Corp now owns 4,950 shares of the company’s stock valued at $171,000 after buying an additional 1,300 shares during the last quarter. Mn Services Vermogensbeheer B.V. increased its position in shares of Hologic by 8.7% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 6,453 shares of the company’s stock valued at $201,000 after buying an additional 517 shares during the last quarter. Nine Chapters Capital Management LLC bought a new position in shares of Hologic during the second quarter valued at approximately $211,000. Finally, Cleararc Capital Inc. bought a new position in shares of Hologic during the first quarter valued at approximately $213,000. 94.51% of the stock is owned by institutional investors and hedge funds.
Hologic Inc. (NASDAQ:HOLX) traded up 0.10% during midday trading on Wednesday, reaching $38.28. 289,801 shares of the company’s stock were exchanged. Hologic Inc. has a 12-month low of $31.84 and a 12-month high of $41.66. The firm has a 50-day moving average price of $38.38 and a 200 day moving average price of $35.84. The company has a market cap of $10.62 billion, a price-to-earnings ratio of 42.21 and a beta of 1.03.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, July 27th. The company reported $0.51 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.48 by $0.03. The firm earned $717.40 million during the quarter, compared to analyst estimates of $703.66 million. Hologic had a net margin of 9.39% and a return on equity of 26.25%. The business’s quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.43 EPS. On average, analysts expect that Hologic Inc. will post $1.94 EPS for the current fiscal year.
Several brokerages recently commented on HOLX. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a research note on Thursday, July 28th. Zacks Investment Research downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Evercore ISI raised shares of Hologic from a “hold” rating to a “buy” rating and increased their price objective for the company from $38.00 to $42.00 in a research note on Thursday, July 28th. Barclays PLC reaffirmed an “equal weight” rating and set a $42.00 price target on shares of Hologic in a research note on Sunday, July 31st. Finally, Morgan Stanley raised their price target on shares of Hologic from $38.00 to $40.00 and gave the company an “equal weight” rating in a research note on Thursday, July 28th. Eight equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $42.35.
In other news, Director Nancy Leaming sold 6,221 shares of the business’s stock in a transaction that occurred on Monday, July 11th. The shares were sold at an average price of $36.04, for a total value of $224,204.84. Following the completion of the sale, the director now directly owns 55,053 shares in the company, valued at approximately $1,984,110.12. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.84% of the stock is currently owned by insiders.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.